Shijiyao Group Co., Ltd. is registered in the Cayman Islands and listed on the main board of the Hong Kong Stock Exchange in 2005. The Group mainly manufactures and sells a wide range of pharmaceuticals, mainly intravenous fluids, through its wholly-owned subsidiary Shijiazhuang Siyao Co., Ltd. in China. Shijiazhuang Siyao was founded in 1948, and its predecessor was a small workshop for the production of hygiene materials. Production of intravenous infusion products began in 1968. After more than 60 years of development, it has now become one of the leading enterprises in the intravenous infusion industry in China. It has the largest single factory for intravenous infusion products in the world. It can produce hundreds of standard intravenous infusion products in various packaging forms such as non-PVC standard soft bags, PP plastic bottles, and glass bottles. The products sell well in the national market, and are also the largest exporter of intravenous infusion products in China. The production line of Shijiazhuang Siyao integrates the world's most advanced equipment and delivery technology, and has achieved full automation and full informatization of the production process and logistics process, reaching the international advanced level. Green production has obvious advantages of low cost, low energy consumption and zero pollution. Based on the business philosophy of “quality for the people, honesty as the foundation”, Shijiazhuang Siyao regards quality as life, organizes production in strict accordance with GMP requirements, establishes and implements superhuman service concepts and initiatives, and has built an excellent “Shimen” brand with excellent product quality. The company's social popularity and reputation have risen all the way up. The company and products have received honors such as “Quality No Complaints Unit”, “Customer Satisfaction Product”, and “China's Famous Trademark”. The Group is dominated by intravenous infusion products, and also takes into account the development, production and operation of small-volume injections, oral preparations, traditional Chinese medicine preparations and biological agents. It is foreseeable that in the near future, these products will also make an important contribution to the company's development.
No Data
No Data